Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes

Medicines and Healthcare products Regulatory Agency (MHRA) has issued a safety alert advising to monitor glucose levels closely in patients with diabetes during direct-acting antiviral therapy for hepatitis C, particularly within the first 3 months of treatment, and modify diabetes medication or doses when necessary.

Further details and advice for healthcare professionals can be found on the MHRA website.